<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030277</url>
  </required_header>
  <id_info>
    <org_study_id>FOCUS-G000280</org_study_id>
    <secondary_id>CDR0000069125</secondary_id>
    <secondary_id>IUMC-010235</secondary_id>
    <secondary_id>NCI-V01-1683</secondary_id>
    <nct_id>NCT00030277</nct_id>
  </id_info>
  <brief_title>High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer</brief_title>
  <official_title>Feasibility Study for Locally Recurrent Prostate Cancer Treatment With HIFU Using the SONABLATE System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Focus Surgery</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Highly focused ultrasound energy may be able to kill cancer cells by heating the&#xD;
      tumor without affecting the surrounding tissue.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying focused ultrasound energy to see how well it works in&#xD;
      treating patients with locally recurrent prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the ability of Sonablate to focus ultrasound waves for the purpose of&#xD;
           selectively destroying prostate cancer tissue, with resultant drop in PSA levels to&#xD;
           below 0.5 ng/mL and negative biopsy for cancer cells, in patients with locally recurrent&#xD;
           prostate cancer.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to prior treatment failure (brachytherapy vs&#xD;
      post-external beam radiotherapy).&#xD;
&#xD;
      A probe is inserted into the rectum. High-intensity focused ultrasound (HIFU) energy using&#xD;
      the Sonablate system is delivered to the prostate tissue over approximately 2 hours. Patients&#xD;
      with residual cancer lesion (by biopsy), PSA greater than 0.5 ng/mL or increasing PSA levels&#xD;
      taken 2 months apart, visible prostate tissue on ultrasound, and no local or distant&#xD;
      metastases after day 90 undergo retreatment with HIFU.&#xD;
&#xD;
      Patients are followed at 2, 14, 30, 90, and 180 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients (10 per stratum) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high-intensity focused ultrasound ablation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed locally recurrent prostate cancer after prior brachytherapy&#xD;
             or external-beam radiotherapy for initial diagnosis of organ-confined disease&#xD;
             (clinical stage T1 or T2 only)&#xD;
&#xD;
               -  Prostatic fossa biopsy positive for cancer cells&#xD;
&#xD;
          -  Gleason score no greater than 7&#xD;
&#xD;
          -  PSA levels 0.5-10 ng/mL&#xD;
&#xD;
          -  Able to adequately visualize local recurrence on transrectal ultrasound imaging&#xD;
&#xD;
          -  No prostate calcification greater than 5 mm&#xD;
&#xD;
          -  No metastases by bone scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  40 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No bleeding disorder as determined by abnormal PT and PTT&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No active urinary tract infection&#xD;
&#xD;
          -  No history of urinary bladder neck contracture&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior allergy to latex&#xD;
&#xD;
          -  No Anesthesia Surgical Assignment (ASA) category IV or greater&#xD;
&#xD;
          -  No interest in future fertility&#xD;
&#xD;
          -  No history of inflammatory bowel disease&#xD;
&#xD;
          -  No other concurrent major nonmalignant debilitating illness&#xD;
&#xD;
          -  No other prior or concurrent malignancy except skin cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy for prostate cancer&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for prostate cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 months since prior hormonal therapy (including finasteride) for prostate&#xD;
             cancer&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior radical prostatectomy&#xD;
&#xD;
          -  No prior transurethral resection of prostate&#xD;
&#xD;
          -  No prior urethral stent&#xD;
&#xD;
          -  No prior major rectal surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior thermotherapy&#xD;
&#xD;
          -  No other prior therapy for prostate cancer&#xD;
&#xD;
          -  No concurrent warfarin or other anticoagulant&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael O. Koch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island College Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

